X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
0
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
GSK, has stopped its Phase II trial of anti-LAG3 cell depleting monoclonal antibody, GSK2831781 (derived from Immutep’s IMP731 antibody), in patients with active ulcerative colitis. The trial was stopped based on the assessment of clinical data of planned interim analysis.
Lead Product(s): IMP731
Therapeutic Area: Gastroenterology Product Name: GSK2831781
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Immutep
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 22, 2021
Details:
GSK, has discontinued its Phase II clinical trial evaluating an anti-LAG3 cell depleting monoclonal antibody, GSK2831781 (IMP731), in patients with active ulcerative colitis. The collaboration remains in place and GSK2831781 continues to be under an exclusive license with GSK.
Lead Product(s): IMP731
Therapeutic Area: Gastroenterology Product Name: GSK2831781
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: GSK
Deal Size: $100.0 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement January 22, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
